MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Regeneron Pharmaceuticals Inc

Open

SectorHealthcare

611.87 -1.67

Overview

Share price change

24h

Current

Min

612.51

Max

626.41

Key metrics

By Trading Economics

Income

-423M

918M

Sales

69M

3.8B

P/E

Sector Avg

16.529

63.778

EPS

12.07

Dividend yield

0.56

Profit margin

24.219

Employees

15,106

EBITDA

-534M

1.1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+51.62% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.56%

2.39%

Next Earnings

29 Apr 2025

Market Stats

By TradingEconomics

Market Cap

-5B

70B

Previous open

613.54

Previous close

611.87

News Sentiment

By Acuity

52%

48%

321 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Regeneron Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Feb 2025, 12:13 UTC

Earnings

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8 Jul 2024, 12:00 UTC

Earnings

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28 Feb 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 Feb 2025, 11:58 UTC

Earnings

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 Feb 2025, 11:37 UTC

Earnings

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 Feb 2025, 11:37 UTC

Earnings

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 Feb 2025, 11:36 UTC

Earnings

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 Feb 2025, 11:35 UTC

Earnings

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 Feb 2025, 11:35 UTC

Earnings

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 Feb 2025, 11:34 UTC

Earnings

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 Feb 2025, 11:34 UTC

Earnings

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 Feb 2025, 11:32 UTC

Earnings

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 Feb 2025, 11:31 UTC

Earnings

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 Jan 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 Jan 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 Oct 2024, 13:58 UTC

Earnings

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 Oct 2024, 10:52 UTC

Earnings

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 Oct 2024, 10:34 UTC

Earnings

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 Oct 2024, 10:33 UTC

Earnings

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 Oct 2024, 10:33 UTC

Earnings

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 Oct 2024, 10:32 UTC

Earnings

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 Oct 2024, 10:30 UTC

Earnings

Regeneron Pharma 3Q Rev $3.72B >REGN

31 Oct 2024, 10:30 UTC

Earnings

Regeneron Pharma 3Q EPS $11.54 >REGN

31 Oct 2024, 10:30 UTC

Earnings

Regeneron Pharma 3Q Net $1.34B >REGN

25 Oct 2024, 20:25 UTC

Earnings

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 Aug 2024, 11:50 UTC

Earnings

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 Aug 2024, 10:37 UTC

Earnings

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 Aug 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q EPS $12.41 >REGN

1 Aug 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q Net $1.43B >REGN

1 Aug 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q Rev $3.55B >REGN

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

51.62% upside

12 Months Forecast

Average 948.55 USD  51.62%

High 1,182 USD

Low 575 USD

Based on 20 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

16

Buy

3

Hold

1

Sell

Technical Score

By Trading Central

N/A / 662.33Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

321 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.